AEZS Aeterna Zentaris Inc.

2.10
+0.13  (7%)
Previous Close 1.97
Open 1.98
Price To book 7.11
Market Cap 34041561
Shares 16,210,267
Volume 1,157,435
Short Ratio 1.28
Av. Daily Volume 3,425,958

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued November 2014. Phase 3 data released January 4, 2017 - trial failed. NDA resubmitted with new PDUFA date of December 30, 2017.
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
Phase 3 trial did not meet primary endpoint - May 1, 2017.
Zoptrex
Endometrial cancer

Latest News

  1. Aeterna Zentaris Announces Departure of Vice President, Finance & Chief Accounting Officer
  2. Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  3. Today's Research Reports on Stocks to Watch: EnteroMedics and Aterna Zentaris
  4. Investor Network: Aeterna Zentaris Inc. to Host Earnings Call
  5. Aeterna Zentaris reports 2Q loss
  6. Aeterna Zentaris Reports Second Quarter 2017 Financial and Operating Results
  7. Aeterna Zentaris Engages Advisors and Provides Update to Shareholders
  8. Aeterna Zentaris to Announce Second Quarter 2017 Financial and Operating Results on August 10, 2017
  9. Aeterna Zentaris Commences Legal Action Against David Dodd and Philip Theodore
  10. Will FDA Catalyst Put Aeterna Zentaris Shares Back on Track?
  11. AEterna Zentaris Inc. (USA) (AEZS) CEO’s Departure Raises Questions
  12. Aeterna Zentaris Forms Strategic Review Committee and Appoints Michael Ward as CEO
  13. Today's Research Reports on Stocks to Watch: Vertex Pharmaceuticals and Aeterna Zentaris
  14. Maxim Hikes Price Targets on 2 Biotech Stocks: AEterna Zentaris Inc. (USA) (AEZS), Vertex Pharmaceuticals Incorporated (VRTX)
  15. AEterna Zentaris's stock more than doubles on heavy volume after favorable FDA ruling
  16. NDA for Macrilen™ for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date
  17. Do Options Traders Know Something About Aeterna Zentaris (AEZS) Stock We Don't?
  18. Aeterna Zentaris Resubmits NDA for Macrilen™ for the Evaluation of Growth Hormone Deficiency in Adults
  19. Implied Volatility Surging for Aeterna Zentaris (AEZS) Stock Options
  20. Aeterna Zentaris to Present at 2017 Marcum MicroCap Conference